Cytokinetics' CEO Robert Blum discusses the result of the MAPLE-HCM study of aficamten, and other learnings from the European Society of Cardiology Congress 2025 | BiotechTV - News | Podwise
Cytokinetics' CEO Robert Blum discusses the result of the MAPLE-HCM study of aficamten, and other learnings from the European Society of Cardiology Congress 2025
BiotechTV - News - Cytokinetics' CEO Robert Blum discusses the result of the MAPLE-HCM study of aficamten, and other learnings from the European Society of Cardiology Congress 2025
Sign in to continue reading, translating and more.
